Quick Summary
• While I would guess we’re still probably at least several years away from 3D printed drugs being a commonplace reality, the growing number of companies with proprietary additive manufacturing (AM)...
Additional Context
While I would guess we’re still probably at least several years away from 3D printed drugs being a commonplace reality, the growing number of companies with proprietary additive manufacturing (AM) for pharmaceutical applications hints that there’s strong demand from the traditional giants of Big Pharma for building up the capability. Of course, we’re also starting to see disruptors bet on AM as a tool that can be leveraged to shift the pharmaceutical industry balance of power.
This is what’s happening with the announcement by Pete Pharma, a Phoenix-based pharmaceutical R&D startup. It has signed a deal with Atrium24, a Florida-based Customer Relationship Management (CRM) enterprise for pharmaceutical vendors. Through the deal, Pete Pharma will become the main provider of 3D printed pharma